Francisco Bevilacqua Guarniero

Learn More
Findings on stigmatizing attitudes toward individuals with schizophrenia have been inconsistent in comparisons between mental health professionals and members of the general public. In this regard, it is important to obtain data from understudied sociocultural settings, and to examine how attitudes toward mental illness vary in such settings. Nationwide(More)
OBJECTIVE To investigate in a community sample the association of suicide-related cognitions and behaviors ("thoughts of death", "desire for death", "suicidal thoughts", and "suicidal attempts") with the comorbidity of depressive disorders (major depressive episode or dysthymia) and alcohol or substance use disorders. METHOD The sample was 1464 subjects(More)
OBJECTIVE Our purpose was to assess stigma toward schizophrenia in a representative sample of the Brazilian general population. METHODS The sample consisted of 1015 individuals interviewed by telephone. A vignette describing someone with schizophrenia was read, and four stigma aspects regarding this hypothetical individual were assessed: stereotypes,(More)
BACKGROUND An important issue concerning the worldwide fight against stigma is the evaluation of psychiatrists' beliefs and attitudes toward schizophrenia and mental illness in general. However, there is as yet no consensus on this matter in the literature, and results vary according to the stigma dimension assessed and to the cultural background of the(More)
CONTEXTO: A estigmatização é uma questão importante no tratamento e no curso da esquizofrenia. A manutenção de atitudes estigmatizantes pode estar relacionada a fatores socioculturais. OBJETIVOS: Comparar atitudes estigmatizantes de profissionais de saúde mental em países culturalmente diversos: Brasil e Suíça. MÉTODOS: Foram analisados dados de duas(More)
1Creativ-Ceutical, Paris, France, 2ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro, 3Reckitt Benckiser Pharmaceuticals, Inc. /NA, Richmond, VA, USA, 4Creativ-Ceutical, Tunis, Tunisia Objectives: Buprenorphine/naloxone (BUP/NAL) combination is a well known treatment for opioid dependence. As a chronic relapsing disorder, some patients alternate(More)
1Creativ-Ceutical, Paris, France, 2ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro, 3Reckitt Benckiser Pharmaceuticals, Inc. /NA, Richmond, VA, USA, 4Creativ-Ceutical, Tunis, Tunisia Objectives: Buprenorphine/naloxone (BUP/NAL) combination is a well known treatment for opioid dependence. As a chronic relapsing disorder, some patients alternate(More)
Schizophrenia, the forgotten disorder: the scenario in Brazil Gabriela Matos, Francisco B. Guarniero, Jaime E. Hallak, Rodrigo A. Bressan Janssen-Cilag Farmacêutica, São Paulo, SP, Brazil. Department of Neurosciences and Behavior, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil. Department of Psychiatry,(More)
OBJECTIVE An important and yet underexplored issue in medical education concerns the extent to which students retain early taught theoretical knowledge during subsequent stages of their academic schooling. This study aimed to assess the degree to which medical students retain basic pathophysiological knowledge on biological psychiatry across different(More)
  • 1